Cytokeratin 5/6
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Cytokeratin 5/6, abbreviated CK/5/6, is a common immunostain.
Use
- Prostatic adenocarcinoma versus high-grade prostatic intraepithelial neoplasia (HGPIN).
- CK5/6 marks the basal cells: present in HGPIN, absent in cancer.
- Urothelial cell carcinoma versus prostatic adenocarcinoma.
- Positive in UCC, negative in prostate adenocarcinoma.
Positive
- Squamous cell carcinoma.
- Benign prostate (basal cells).[2]
- Urothelial carcinoma.
- Malignant mesothelioma.[3]
- Reactive mesothelial cells.[4]
Negative
See also
References
- ↑ Ma, Y.; Fan, M.; Dai, L.; Kang, X.; Liu, Y.; Sun, Y.; Xiong, H.; Liang, Z. et al. (May 2015). "Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis.". Thorac Cancer 6 (3): 288-95. doi:10.1111/1759-7714.12181. PMID 26273374.
- ↑ Trpkov, K.; Bartczak-McKay, J.; Yilmaz, A. (Aug 2009). "Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.". Am J Clin Pathol 132 (2): 211-20; quiz 307. doi:10.1309/AJCPGFJP83IXZEUR. PMID 19605815.
- ↑ 3.0 3.1 Marchevsky AM (March 2008). "Application of immunohistochemistry to the diagnosis of malignant mesothelioma". Arch. Pathol. Lab. Med. 132 (3): 397-401. PMID 18318582. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=397.
- ↑ Yan, J.; Wei, Q.; Jian, W.; Liu, J.; Tang, H.; Ge, J.; Zhou, J.; Zhao, T. (2014). "A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.". Int J Clin Exp Pathol 7 (9): 5810-8. PMID 25337222.